Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04598698 · ClinicalTrials.gov registry record
The EMPOWER Study: Endometriosis Diagnosis Using MicroRNA
A clinical trial of Endometriosis, sponsored by Dot Laboratories.
- Active
- Registry status
- 750
- Enrollment target
- 20
- Study locations
NCT04598698: Active study of Endometriosis, sponsored by Dot Laboratories.
NCT04598698 is a study of Endometriosis that is active but no longer recruiting, run by Dot Laboratories. The registered enrollment target is 750 participants, above the 249-participant average among 48 other Endometriosis trials with a reported enrollment target (201% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04598698, a study of Endometriosis, is active but no longer recruiting, sponsored by Dot Laboratories.
- ACTIVE NOT RECRUITING
- Registry status
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visits for collection of blood and saliva and completion of study questionnaires.
Conditions Studied
Study Locations (20)
Illinois
- Northwestern Medicine - Chicago
- NorthShore University HealthSystem - Evanston
- The Advanced Gynecologic Surgery Institute - Park Ridge
California
- Stanford University Hospital - Palo Alto
- Center for Special Minimally Invasive & Robotic Surgery - Woodside
Delaware
- Christiana Care - Newark
- RAD Fertility - Newark
Ohio
- University Hospitals - Cleveland
- Cleveland Clinic - Cleveland
Pennsylvania
- Penn State Health - Hershey
- Hospital of the University of Pennsylvania - Philadelphia
Connecticut
- Yale University - New Haven
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2024-12 |
What the registry record for NCT04598698 still lists
NCT04598698 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 249-participant average among 48 other Endometriosis trials with a reported enrollment target (201% higher).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 0 interventions.
NCT04598698 names 20 study sites across 14 states, led by Illinois, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT04598698 about?
NCT04598698 is a clinical study titled "The EMPOWER Study: Endometriosis Diagnosis Using MicroRNA". Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal ris...
What is the current status of trial NCT04598698?
This trial is currently active not recruiting. The enrollment target is 750 participants. The study started on 2020-11-02. Estimated completion is 2024-12.
What conditions does trial NCT04598698 study?
This clinical trial studies the following conditions: Endometriosis.
Who is sponsoring clinical trial NCT04598698?
This trial is sponsored by Dot Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04598698 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04598698's enrollment target sits among peer trials
750 8th of 48 higher than 41 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
-
The Impact of Yoga on Endometriosis-Related Pain
RECRUITING · NA
-
Endometriosis and Microvascular Dysfunction: Role of Inflammation
RECRUITING · Early Phase 1
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI